NR3C1
Glucocorticoid receptor
As of the edition of 20 October 2026, NR3C1 (glucocorticoid receptor, UniProt P04150) has 92 drugs tested at it and 135 companies on the list, 4 on route A and 24 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- P04150
- How well studied
- Drug target: an approved drug acts on it
- Where it sits in the cell
- Inside the cell
- Solved structures
- 58
- Disease areas
- Immune system; Cancer; Blood and lymph; Lungs and airways; Heart and blood vessels; Urinary and reproductive; Infections; Nervous system
- Registered trials of its drugs
- 6,392
Drugs at this target
| Status | Count |
|---|---|
| Marketed | 70 |
| Active | 4 |
| Went quiet | 12 |
| Stopped | 4 |
| Status not established | 2 |
| Total | 92 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Dexamethasone | Marketed | Phase 4 | none listed |
| Prednisone | Marketed | Phase 4 | none listed |
| Methylprednisolone | Marketed | Phase 4 | none listed |
| Prednisolone | Marketed | Phase 4 | none listed |
| Budesonide | Marketed | Phase 4 | Ends 2029 |
| Hydrocortisone | Marketed | Phase 4 | none listed |
| Fluticasone propionate | Marketed | Phase 4 | none listed |
| Triamcinolone acetonide | Marketed | Phase 4 | none listed |
| Mifepristone | Marketed | Phase 4 | none listed |
| Mometasone furoate | Marketed | Phase 4 | none listed |
| Fluticasone furoate | Marketed | Phase 4 | Ends 2027 |
| Fluticasone | Marketed | Phase 4 | none listed |
12 of 92 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route A | 4 |
| Route B | 24 |
| Engaged | 74 |
| Undetermined | 33 |
| Total on the list | 135 |
The other 132 companies at NR3C1
In the product135 companies in all; 132 are not named here, and no score is.
See the 135 companies at NR3C1, ranked, with the facts behind eachRequest access. Nothing is shown until you do.